Verition Fund Management
TVGN icon

Verition Fund Management’s Tevogen Bio Holdings TVGN Stock Holding History

Verition Fund Management’s Portfolio TVGN Stock Details TVGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-4,000
Closed -$2.07M – 2627
2022
Q4 		$2.07M Sell
4,000
-6,812
-63% -$3.49M 0.03% 608
2022
Q3 		$5.49M Hold
10,812
– – 0.06% 375
2022
Q2 		$5.41M Hold
10,812
– – 0.11% 241
2022
Q1 		$5.4M Buy
+10,812
New +$5.38M 0.06% 352

Other funds holding TVGN

CCP
Corbin Capital Partners New York $61.3M AUM 53.03% 1-Year Est. Return
FCM
FourWorld Capital Management New York $196M AUM 42.39% 1-Year Est. Return
CF
Cantor Fitzgerald New York $6.78B AUM 29.01% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Verition Fund Management's TVGN Position: Q1 2023 in Review

Verition Fund Management sold out of Tevogen Bio Holdings (TVGN) in Q1 2023, closing a stake of 4,000 shares — an estimated $2.07M sold.

Verition Fund Management first reported a position in TVGN in Q1 2022 and held it in 4 quarters. The position peaked at $5.49M in Q3 2022. 4 funds tracked by Wall St. Rank hold TVGN as of Q1 2023.

  • Verition Fund Management reported no remaining Tevogen Bio Holdings position as of Q1 2023 after selling out during the quarter.
  • Verition Fund Management sold 4,000 Tevogen Bio Holdings shares in Q1 2023, an estimated $2.07M.
  • Verition Fund Management first reported a position in Tevogen Bio Holdings in Q1 2022 and held it in 4 quarters.
  • Verition Fund Management's Tevogen Bio Holdings position peaked at $5.49M in Q3 2022.
  • 4 funds tracked by Wall St. Rank held Tevogen Bio Holdings as of Q1 2023.

Based on Verition Fund Management's 13F filing for Q1 2023, filed 15 May 2023.